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Abstract
Hepatocellular carcinoma (HCC) is a major health problem worldwide. The DNA PM of 
cancer-related genes plays an important role in the development and progression of HCC. 
The data reported in our studies provide evidence that PM of p73, p14, and O6-MGMT is 
associated with HCC, whereas PM of the APC gene is more common in chronic hepatitis 
(CH) cases. Thus, it could be used as a maker for early detection of HCV-induced chronic 
active hepatitis. A panel of four genes APC, p73, p14, and O6-MGMT independently 
affected the classification of cases into HCC and CH with accuracy (89.9%), sensitivity 
(83.9%), and specificity (94.7%). Also, the detection of PM of APC, FHIT, p15, p16, and 
E-cadherin in peripheral blood of HCV-infected patients is a highly sensitive and specific. 
Therefore, blood could be used as efficiently as tissue biopsies to assess PM of different 
genes. This could help in the follow-up of CH patients and early detection of HCC. We did 
not observe a significant difference in the methylation status according to the virus type 
HBV versus HCV. So, plasma DNA is a reliable resource for methylation studies in the 
future, irrespective of the type of hepatitis infection.
Keywords: hepatitis C virus-genotype 4, chronic hepatitis, hepatocellular carcinoma, 
promoter methylation
1. Introduction
Hepatocellular carcinoma (HCC) is a major health problem and it is the third most com-
mon cause of cancer-related death worldwide [1]. In Egypt HCC ranks the first in males 
and the second in females after breast cancer. It accounted for 33.6% in males and 13.5% 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
in females [2]. This high incidence of HCC is attributed to the high prevalence of HCV 
infection, especially genotype 4 in Egypt [3]. HCV infection has an estimated global prev-
alence of 2.5%, causing chronic liver disease in about 170 million people worldwide [4]. 
Although it has been estimated that 80% of HCC occurs in cirrhotic livers, the underlying 
molecular mechanisms of virus associated hepatocarcinogenesis are still unclear [5]. It has 
been suggested that HCV-encoded proteins may contribute to tumor progression through 
their direct and indirect interactions with host hepatic cells. Additionally, the generated 
status of chronic HCV inflammation is accompanied by immune-mediated destruction of 
infected hepatocytes, oxidative stress, virus-induced apoptosis and DNA damage leading 
to genomic instability and continuous regeneration that may be incorporated in liver cancer 
development [6].
Previous studies demonstrated that DNA methylation has a major role in the initiation and 
progression of various types of human cancers [7, 8]. Aberrant promoter methylation of 
tumor suppressor genes (TSGs), such as P14 or O6-methylguanine-DNA methyltransferase 
(O6MGMT) has been reported in relation to HCC development [9].
The term DNA methylation refers to the addition of a methyl group to the cytosine residue 
in the CpG islands. Normally, CpG islands are not methylated regardless of their transcrip-
tional status, and methylation of the promoter regions of tumor suppressor genes (TSGs) 
or growth regulatory genes resulted in silencing of those genes, and cancer development. 
Since it was proven that different types of cancer showed distinct DNA methylation pro-
files, thus it could be possible to develop specific methylation signatures for those types of 
cancer [10].
The power of PM as a molecular marker is the ability of detecting its presence in a variety 
of sample types including fresh specimens, body fluids and archival paraffin-embedded tis-
sues, as well as to the defined localization of the lesion in the CpG islands of the genes. 
Promoter methylation could be an important early event in the cascade of carcinogenesis and 
it can also be of important as prognostic and predictive marker [11]. The DNA methylation 
profiles in HCV-infected patients from Egypt have not been well studied yet, although it has 
the highest prevalence of HCV infection worldwide with approximately 14% of the popula-
tion infected [12].
2. Concordance between tissue and plasma DNA methylation in 
HCC patients
Owing to the crucial effects of DNA promotor methylation in the development and pro-
gression of HCC, we investigated the role of DNA methylation events in the tissues of HCC 
patients for using five tumor suppressor genes: APC, FHIT, p15, p16, and E-cadherin. We also 
assessed the DNA methylation patterns of these genes in the plasma from the same patients 
and compared the tissue and plasma patterns [13]. This was done to investigate the concor-
dance between tissue and plasma methylation patterns in Egyptian patients with HCV and/
or HBV- associated HCC. Although liver biopsy is the current gold standard for detecting 
methylation events, imaging techniques are usually sufficient for liver cancer diagnosis and 
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therefore the need of tissue biopsy decreased markedly [14]. So it was essential to search for 
another tool for detection of promotor methylation in HCC by a simpler, easy and reliable 
technique.
Figure 1. Summary of methylation analysis of APC, FHIT, p15, p16, and E-cadherin in 28 HCC samples and the 
corresponding plasma. Filled boxes indicate the presence of methylation and open boxes indicate the absence of 
methylation. T, tumor tissue; P, plasma.
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We collected paired blood and tissue samples from 28 HCV and/or HBV- associated HCC 
patients from Egypt. DNA was extracted from those patients (tissue and blood) and the pro-
motor methylation for APC, FHIT, p15, p16, and E-cadherin tumor suppressor genes were 
assessed using the EZ DNA Methylation-Direct TM Kit according to manufacturer’s protocol.
We reported a statistically significant concordance between plasma and tissue methylation 
profiles [13]. The frequency of promoter methylation in tissue and plasma samples for the 
five tumor suppressor genes was as follows: APC promoter methylation was accounted for 
approximately 64.2% for tissue (18/28), and 53.5% for plasma (15/28), FHIT promoter meth-
ylation was accounted for 75.0% for tissue (21/28), and 67.8% for plasma (19/28), p15 pro-
moter methylation was accounted for 14.2% for tissue (4/28), and 10.7% for plasma (3/28), p16 
promoter methylation was accounted for approximately 71.4% for tissue (20/28) and 46.4% 
for plasma (13/28), and E-cadherin promoter methylation was accounted for 67.8% for tissue 
(19/28) and 46.4% for plasma (13/28) (Figure 1).
Although detection of promoter methylation in the plasma DNA was highly specific, it was not 
as sensitive for the matching change in tissue DNA, suggesting that DNA promotor methyl-
ation in tissues might originate in tumor cells before appearing in the vascular spaces (blood 
or plasma). The positive predictive value (PPV) was higher than the negative predictive value 
(NPV) for APC, FHIT, p16, and E-cadherin whereas, the negative predictive value was higher for 
p15 (Table 1). Therefore, a previous study by Huang et al., [15] concluded that it may be useful 
to combine the plasma DNA methylation status of ELF, RASSF1A, p16, and GSTP1 with serum 
AFP for HCC screening and several studies had confirmed these data [16, 17]. However contro-
versial results were reported by Chang et al. [18] who found no agreement between plasma and 
tissue DNA samples. One possible explanation for the controversy in the results between the pre-
viously mentioned studies could be the small sample size in the study of Chang et al. (eight HCC 
patients only) and/or the use of RT-PCR which causes DNA degradation during amplification.
3. Methylation profile and viral status
Another interesting finding observed is that, there was no significant correlation between 
HBV or HCV infection and the incidence of promoter methylation, to suggest whether the 
viral status could be used to predict methylation and subsequent gene silencing for the five 
Genes Sensitivity (%) Specificity (%) PPV (%) NPV (%) p-Value
APC 77.8 90.0 93.3 69.2 0.001*
FHIT 85.7 85.7 90.5 66.7 0.001*
p15 50.0 95.8 66.7 92.0 0.045*
p16 60.0 87.5 92.3 46.7 0.037*
E-cadherin 68.4 100.0 100.0 60.0 0.0008*
PPV, positive predictive value; NPV, negative predictive value.*The concordance was significant for all five genes.
Table 1. The concordance between plasma DNA and tissue DNA.
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aforementioned tumor suppressor genes [13]. Therefore, plasma DNA could be used as a 
reliable source for methylation detection in HCC patients irrespective of the type of hepatitis 
viral infection (Table 2).
4. Increasing DNA promoter methylation is associated with disease 
progression from chronic hepatitis C to cirrhosis and hepatocellular 
carcinoma
As a continuation of our previous studies, which showed a concordance between tissue and 
plasma DNA methylation, and hence the validity of using plasma DNA methylation profile as a 
marker for HCC [13], we had assessed the methylation frequency of three tumor suppressor genes 
(P14, P15, P73) and a mismatch repair gene (O6MGMT) in the plasma of 516 Egyptian patients 
with HCV-related liver disease, during the period from 2010 to 2012, to identify candidate epi-
genetic biomarkers for prediction of HCC [19]. Subjects were divided into 4 clinically well-defined 
groups as follow: the HCC group (n = 208), liver cirrhosis group (LC; n = 108), chronic hepatitis C 
group (CH; n = 100), and normal control group (NC; n = 100). The methylation status of the target 
genes was analyzed in patients’ plasma using EpiTect Methyl qPCR Array technology. According 
to the manufacturer’s instructions, the four studied genes (P14, P15, P73 and O6MGMT) were 
considered methylated if >10% and intermediately methylated if >60%.
We found significant differences in the frequency of PM of all studied genes within the dif-
ferent stages of chronic liver disease and HCC (Table 3 and Figure 2). The methylation fre-
quency of P14 gene was 48.1% (100/208) in HCC, 48.1% (52/108) in LC, 16% (16/100) in CH and 
8% (8/100) in NC. Out of the studied patients 32/208 (15.4%), 16/108 (14.8%) and 8/100 (8%) 
were intermediately methylated in HCC, LC and chronic hepatitis C groups respectively, 
with a statistically significant difference between the studied groups (p = 0.008). Accordingly, 
p14 is preferentially methylated in HCV related HCC [20].
As for p15, the methylation frequency was 44.2% (92/208) in HCC, 33.3% (36/108) in LC, 20% 
(20/100) in CH and 4% (4/100) in NC. While intermediate methylation was found in 32/208 
(15.4%) of HCC, 20/108 (18.5%) in LC, in 8/100 (8%) CH and 4/100 (4%) in NC with a statisti-
cally significant difference between the studied groups (p = 0.006).
HBV HCV HBV infection type*
APC 0.107 0.634 0.508
FHIT 0.545 1 0.508
p15 0.481 1 0.288
p16 0.295 0.639 1
E-cadherin 0.273 0.629 0.66
The methylation profile was not significantly associated with the HBV, HCV, or *HBV Infection type: past infection or 
immune.
Table 2. Statistical association of hepatitis viral status and promoter methylation.
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The methylation frequency of O6MGMT gene was 40.4% (84/208) in HCC, 55.6% (60/108) in 
LC, 20% (20/100) in CH and 4% (4/100) in NC. While intermediately methylated in 48/208 
(23.1%) in HCC and 36/108 (33.3%) in LC, with a statistically significant difference between 
the studied groups (p value<0.001).
Gene HCC HCV with liver cirrhosis Chronic Hepatitis C Control p value
n = 208(%) n = 108(%) n = 100(%) n = 100(%)
P14 M 100 (48.1) 52 (48.1) 16 (16) 8 (8) 0.008
U 108 (51.9) 56 (51.9) 84 (84) 92 (92)
P15 M 92 (44.2) 36 (33.3) 20 (20) 4 (4) 0.006
U 116 (55.8) 72 (66.7) 80 (80) 96 (96)
O6MGMT M 84 (40.4) 60 (55.6) 20 (20) 4 (4) <0.001
U 124 (59.6) 48 (44.4) 80 (80) 96 (96)
P73 M 136 (65.4) 72 (66.7) 32 (32) 4 (4) <0.001
U 72 (34.6) 36 (33.3) 68 (68) 96 (96)
Methylated (M); Unmethylated (U).
Table 3. Methylation frequency of P14, P15, O6MGMT and P73 genes in different studied groups.
Figure 2. Methylation frequency of (A) P14 gene; (B) P15 gene; (C) O6MGMT gene; and (D) P73 gene in the studied groups.
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The methylation frequency of P73 gene was detected in 65.4% (136/208) in HCC, 66.7% 
(72/108) in LC, 32% (32/100) in CH and 4% (4/100) in NC. While intermediate methylation 
was found in 88/208 (42.3%) in HCC, 56/108 (51.9%) in LC, 24/100 (24%) in CH and 4/100 (4%) 
in NC, with a statistically significant difference between the studied groups (p value<0.001). 
Statistically significant differences were reported among the four studied groups regarding 
the PM of all studied genes (Table 4).
Thus, it could be concluded that, the methylation frequency increases with the progression of 
liver disease and thus it that could be used to monitor whether a patient with chronic hepatitis 
C is likely to progress to liver cirrhosis or even HCC or not. Moreover, the process of PM does 
not represent an early event in hepatocarcinogenesis cascade but it increases and continues 
with disease progression to cancer.
Based on our data regarding the high methylation frequency of APC, FHIT, CDH1 and p16 
in the plasma and tissues of HBV and HCV-associated HCC patients from Egypt [13] we 
sought to confirm this data in a larger cohort of HCV-genotype-4 infected patients using a 
larger panel of 11 genes (p14, p15, p16, p73, APC, FHIT, DAPK1, CDH1, RARb, RASSF1A, and 
O6MGMT). The newly tested group included (1) asymptomatic carriers, (2) CH patients with 
cirrhosis and (3) HCC. PM of the 11 genes were assessed in the Peripheral Blood Lymphocytes 
(PBLs) and the tissues of 31 HCC with their adjacent normal tissue (ANT), 38 CH and 13 
normal hepatic tissue (NHT); which represents the progression from NHT to HCC in the 
HCV genotype 4-infected persons [21]. Promotor methylation of these genes was assessed 
by methylation-specific PCR (MSP). APC and O6-MGMT protein expression was assessed by 
immunohistochemistry (IHC) in the studied HCC and CH tissue samples.
HCC Cirrhosis Chronic hepatitis C Control
P14 HCC 0.954a 0.035b 0.004c
Cirrhosis 0.050d 0.004e
Chronic C 0.546f
Control
P15 HCC 0.409a 0.090b <0.001c
Cirrhosis 0.554d 0.024e
Chronic C 0.223f
Control
MGMT HCC 0.328a 0.016b 0.003c
Cirrhosis 0.002d <0.001e
Chronic C 0.189f
Control
TP73 HCC 0.858a 0.037b <0.001c
Cirrhosis 0.058d <0.001e
Chronic C 0.026f
Control
Table 4. Pairwise comparison among the studied groups.
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5. Analysis of DNA methylation events of the 11 tested genes among 
the studied groups
A high methylation frequency was reported for all studied genes (except for p15) in the PBL 
and tissues with increasing methylation index as the disease progresses (Figure 3). The PM of 
the 11 tested genes assessed in 13 NHT samples showed no methylation events in p15, p73, 
RARb, RASS, F1A or O6MGMT. However p14 PM was estimated in 46.2% of the cases fol-
lowed by APC which was methylated in 30.8% of the cases. There was a significant difference 
in MF between NHT and CH groups regarding APC, FHIT, DAPK and RASSF genes. Also 
MF of p14, p73, RASSF1A, CDH1 and O6MGMT was significantly higher in HCC and their 
ANT. However MF of APC was higher in CH (Figure 4 and Table 5). Among the four groups 
enrolled (HCC, CH, ASC, NHT) binary logistic regression in PROC LOGISTIC for each gene 
was used. Our results indicate that there is a significant interaction between disease state (dif-
ferent groups) and DNA methylation of the tested genes (Figure 5a–k). As shown in Figure 6, 
there is a significant group effect for APC (ASC group is different from HCC Group, p = 0.0006). 
This interaction is explained by the fact that there is a bigger difference between methylation 
and un-methylation for the CH group compared to any other group, especially the NHT. For 
DAPK1 (Figure 5g), there is a marginal group effect, not significant by our corrected level of 
Figure 3. Methylation-specific PCR analyses of nine representative HCC samples (labeled 1–9 on the top). Each gene is 
indicated on the right. Both methylated (M) and unmethylated (U) reactions were amplified for each bisulfite-treated 
DNA and run in a 4% agarose gel.
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P = 0.004 (NHT is significantly different from HCC P = 0.007) and RARb (Figure 5h) (NHT is 
different from-HCC Group P = 0.007). In contrast, there were significant methylation effects for 
APC p < 0.0001), FHIT (P < 0.0001), p15, (P = 0.003), p14 (P < 0.0001), DAPK1 (P < 0.0001), RARb 
(P < 0.0001) and E-cadherin (P < 0.0001).
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Figure 4. (A) Methylation of 11 genes in hepatocellular carcinoma patients; (B) Methylation of 11 genes in patients with 
chronic liver diseases; (C) Methylation of 11 genes in normal liver individuals. Dark squares depict methylation and 
blank squares depict unmethylation.
Genes Normal liver 
N = 13 (%)
Chronic hepatitis (CH) Hepatocellular 
carcinoma HCC
p-Value*
(Tissue) (38) 
(%)
(PBL) (20) 
(%)
(HCC) (31) 
(%)
(ANT) (31) 
(%)
(CH and 
HCC)
(CH and 
ANT)
APC 4 (30.8) 33 (86.8) 16 (80) 13 (41.9) 14 (45.2) <0.001 <0.001
FHIT 2 (15.4) 20 (52.6) 6 (30) 21 (67.7) 20 (64.5) 0.204 0.005
P15 0 (0) 0 (0) 0 (0) 5 (16.1) 5 (16.1) 0.010 #
P73 0 (0) 8 (21.1) 1 (5.0) 26 (83.9) 23 (74.2) <0.001 <0.001
P14 6 (46.2) 17 (44.7) 10 (50) 28 (90.3) 28 (90.3) <0.001 <0.001
P16 3 (23.1) 15 (39.5) 9 (45) 14 (45.2) 19 (61.3) 0.634 0.390
DAPK 3 (23.1) 22 (57.9) 12 (60) 21 (67.7) 22 (71) 0.401 0.023
RARb 0 (0) 0 (00) 0 (0) 5 (16.1) 3 (9.7) 0.015 #
RASSF 0 (0) 26 (68.4) 20 (100) 31 (100) 31 (100) 0.001 <0.001
O6O6-MGMT 0 (0) 10 (26.3) 10 (50.0) 21 (67.7) 20 (64.5) <0.001 <0.001
CDH1 3 (23.1) 7 (18.4) 8 (40.0) 17 (54.8) 14 (45.2) 0.002 0.004
*p-Values <0.05 are considered significant. #Numbers are too small for a valid statistical analysis.
Table 5. Methylation profile of the 11 genes in CH, HCC and normal liver tissues.
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Our data regarding the p15 gene confirms our previous study in which p15 methylation was 
reported in 14.2% only of HCC cases [13, 19]. Within the studied groups, the methylation 
frequency of p14, p73, RASSF1A and O6MGMT was significantly higher in HCC and their 
ANT compared to CH and the NHT samples, whereas PM of APC was significantly higher 
in CH patients compared to all other groups. This was applied to PBL and tissues except for 
RASSF1A and O6MGMT in which the difference in the MF in PBL was statistically insignifi-
cant (Figure 7).
RASSF1A is a candidate TSG, which frequently shows PM and loss of heterozygosity (LOH) 
with consequent gene silencing in several human cancers [22]. The high MF reported here 
confirms the results of some recent studies including those of Qu and Lia [23, 24] who found 
PM of RASSF1A gene in 78 and 95% of HCC cases assessed. In our study, RASSF1A meth-
ylation was detected in all HCC cases and in 68.4% of CH cases (being second only to APC). 
This finding is consistent with Araújo and Gioia et al. [25, 26] who reported an increase in 
RASSF1A PM with progression from regenerative conditions (e.g. cirrhosis) to hepatocellu-
lar nodules and HCC, as well as with Huang et al. [15] and Chan et al. [27] who reported 
RASSF1A methylation in the blood and tissues of HCC patients. Our results also showed an 
increasing frequency of p16 PM from NHT to HCC which is in agreement with the earlier 
studies [28, 29].
Figure 5. Differences in the methylation frequency among the four studied groups. (T = HCC, C = CAH with cirrhosis, 
A = asymptomatic carrier and B = normal hepatic tissue).
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Figure 6. Differences across methylation profiles between HCC\cases and their ANT# samples with 0.0045 as a cut-off 
for significance. *HCC = T. # ANT = N. a-k: names of the studied genes.
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6. Genes methylation could be used as a biomarker for diagnosis of 
HCC and CH
The Coordination of methylation at the 11 tested genes was analyzed in our study using the 
Mann–Whitney U test through comparing the status of each gene (M or U) with the MI cal-
culated with the remaining genes (Table 6). The combined effect of the studied methylated 
genes as biomarkers for diagnosis of HCC and CH has been determined (assessed) using the 
stepwise logistic regression, and accordingly only APC, p73, p14 and O6MGMT indepen-
dently affected the classification of cases into HCC and/or CH (Table 7). Together, these four 
genes (combined) give an accuracy of 89.9%, sensitivity 83.9% and specificity 94.7%.
Figure 7. Differences across methylation profiles within CAH\cases between tissues and PBL. a-k: names of the studied genes.
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Within the identified genes panel which independently affected the classification of cases into 
HCC and CH in this study, p14 only showed a high MF in HCC cases. Our data in this context 
confirmed those of Anzola et al. [30] and Yang et al. [20] who reported that p14 PM is an impor-
tant factor contributing for the development of HCV-induced HCC. The fact that we were able 
to detect p14-PM in NHT and CH with almost the same frequency, suggests that it might be an 
early event in the cascade of HCV-induced HCC. On contrary, we could not find the same pro-
file for p16PM suggesting that p14 and p16 are may be regulated by different promoters [31].
Similar to p14, O6MGMT plays an important role in cytoprotection by preventing DNA dam-
age and triggering DNA repair mechanisms [32]. Our results showed a significant increase 
in the frequency of O6MGMT PM from CH (26%) to HCC (67.7%) providing an evidence 
that this gene could be used to differentiate between CH and HCC. We have also reported 
that O6MGMT PM is significantly higher in non-responder to antiviral therapy, and conse-
quently O6MGMT could be used as a predictor for antiviral response [33]. Literature reviews 
shows different frequencies of O6MGMT PM in HCC ranging from 0% to 22–39% [34, 35]. 
This  variability in the results among different studies could be attributed to several factors 
including the sensitivity and type of PCR, the primer sequences used, the site of CpG islands, 
the geographical and the underlying etiological factors that promoting HCC development 
Factor Concordance, n=31 (n (%)) Kappa# p-Value*
APC 28 (90.3) 0.803 <0.001
FHIT 24 (77.4) 0.497 0.006
P15 31 (100.0) 1.000 <0.001
P73 18 (58.1) −0.248 0.150
P14 31 (100.0) 1.000 <0.001
P16 24 (77.4) 0.558 0.001
DAPK 22 (71.0) 0.318 0.076
RARb 27 (87.1) 0.431 0.012
RASSF 31 (100.0) — —
O6O6-MGMT 26 (83.9) 0.640 <0.001
CDH1 22 (71.0) 0.425 0.016
– Numbers are too small for a valid statistical analysis.#Kappa measure of agreement.
*p-Values<0.05 are considered significant.
Table 6. Summary of methylation specific PCR results and concordance tests of each locus in HCC samples.
Parameter Regression estimate P value Odds ratio 95% CI for OR
APC −3.606 0.003 0.027 0.003 0.287
p73 3.671 0.001 39.302 4.752 325.017
P14 3.638 0.009 38.014 2.492 579.829
O6-MGMT 2.589 0.014 13.311 1.685 105.132
Table 7. Stepwise logistic regression for HCC.
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[24, 35]. And finally, p73 PM was reported in 83.9% of the HCC cases assessed in our study 
compared to 21.1% in CH and none in the NHT samples. Thus p73 PM could be used to dif-
ferentiate between CH and HCC cases even in patient’s blood [32].
A significant difference in the MFs of APC and CDH1 were found between CH and HCC cases. 
APC was more frequent in the CH and CDH1 in HCC. APC and CDH1 PM was reported by 
Yang et al. [20] who demonstrated that PM of APC and CDH1 are more frequent in HBV and 
Figure 8. (A) Normal hepatic tissue sample showing positive cytoplasmic immunostaining for APC (200×). (B) A case 
of HCV induced chronic hepatitis showing mild focal cytoplasmic immunostaining for APC (100×). (C) A case of HCV 
induced chronic hepatitis with cirrhosis negative for APC (100×). D: A case of HCV-associated HCC negative for APC 
(100×). (E) A case of HCV-associated HCC with positive cytoplasmic immunostaining for APC (40×). (F) Normal hepatic 
tissue negative for MGMT (100×). (G) A case of HCV-induced chronic hepatitis with cirrhosis negative for MGMT (100×). 
(H) A case of HCV-induced chronic hepatitis with cirrhosis positive for MGMT immunostaining (100×). (I) A case of 
HCV-induced HCC with marked cytoplasmic immunostaining for MGMT (200×). (J) A case of HCV-induced HCC 
showing faint cytoplasmic immunostaining for MGMT (200×).
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HCV-positive HCC than in HBV and HCV negative ones. Nomoto et al. [34] founded APC 
PM in 88.2% of the NHT and 21.6% in CH with cirrhosis compared to 82.4% in HCC. They 
explained that APC loss in cirrhotic and inflammatory cases could be occurred due to the 
presence of inflammatory cells and fibroblasts. However in contrast, we reported a high APC 
MF in the blood and tissues of CH patients. This contradictory between our results and those 
of Nomoto et al. could be attributed to (a) their smaller sample size (19 cases only); (b) the 
samples of CH and cirrhosis were obtained from HCC cases in their study or (c) a possibly 
different underlying etiology as viral infection was not mentioned in their study.
7. Concordance between PM and protein expression of APC and 
O6MGMT
We assessed the protein expression of APC and O6MGMT in 20 NHT samples, 20 HCC and 
20 CH tissues as well as in another group of samples including 40 NHT, 52 CH and 107 HCC 
tissue samples for confirmation of the methylation results [21]. In the original set, cytoplasmic 
immunostaining for the APC was detected in 11 cases of NHT (55%), with loss of staining 
in 10 CH cases (50%), and 15 cases of HCC group (75%). As for the confirmatory set, cyto-
plasmic immunostaining for the APC was present in 50% of NHT (20 cases), with loss of 
staining in 57.7% of CH (30 cases), and 72% of HCCs (77 patients). Nuclear immunostaining 
for O6MGMT protein was detected in 13 patients with NHT (65%), with loss of expression 
in 11 patients with CH (55%) and 16 patients with HCCs (80%), from the original set. In the 
confirmatory set O6MGMT protein was lost in 26 patients with CH accounting for 50%, and 
70 patients with HCC accounting for 65.4% (Figure 8).
8. Conclusion
We conclude that DNA PM of multiple cancer-related genes plays an important role in the 
development and progression of HCC and therefore, it could be detected in different stages of 
disease progression from hepatitis to HCC. The data reported in our study provide evidence 
that PM of p73, p14, O6- MGMT is associated with HCC whereas PM of the APC gene is more 
common in CH cases compared to other groups. Therefore, APC PM could be used as a maker 
for early detection of HCV-induced chronic active hepatitis patients.
Moreover, a panel of four genes (APC, p73, p14, O6-MGMT) independently affected the classifi-
cation of cases into HCC and CH with high accuracy (89.9%), sensitivity (83.9%) and specificity 
(94.7%). In addition, detection of PM of certain genes (APC, FHIT, p15, p16, and E-cadherin) in the 
PBL of HCV-infected patients is a highly sensitive and specific, noninvasive way (technique) 
and therefore, blood could be used, as efficiently as tissue biopsies, to assess PM of different 
genes. This could help in the follow-up of chronic hepatitis patients and  possibly for early detec-
tion of HCC. We did not observe a significant difference in the methylation status according to 
the virus type (HBV versus HCV infection). Therefore, plasma DNA could be used as a reliable 
resource for methylation studies in the future, irrespective of the type of hepatitis infection.
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